Trans-Tasman Mutual Recognition (South Australia) Regulations 2015

These regulations, made under the Trans‑Tasman Mutual Recognition (South Australia) Act 1999 (the Act), declare time‑limited exemptions from the operation of the referenced Commonwealth Act for specific controlled substances and for specified provisions of South Australian subordinate instruments that refer to those substances. Mechanically the instrument does three things, each by regulation:

• Regulation 4 declares the substances listed in Schedule 1, and the provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 inserted by the Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015, to be exempt from the operation of the Commonwealth Act (r 4(1)(a)-(b)). Those exemptions are made “for the purposes of section 5 of the Act and section 46 of the Commonwealth Act” (r 4(1)) and have an express time limit of 12 months from the commencement of that regulation (r 4(2)).

• Regulation 5 performs the same form of declaration but single‑out the chemical methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate, known as MDMB‑CHMICA, and any preparation containing it (r 5(1)(a)), together with the specific provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 that refer to that substance (r 5(1)(b)). The r 5 exemptions also run for 12 months from commencement (r 5(2)).

• Regulation 6 declares a further list of named substances and preparations containing them to be exempt from the operation of the Commonwealth Act (r 6(1)(a)), and declares the 2017 variation provisions of the Controlled Substances Regulations that refer to those substances to be exempt as well (r 6(1)(b)). That regulation lists the individual substances and categories at r 6(3) (for example, acetyl fentanyl, U‑47700, a range of fentanyls and benzamide derivatives) and again constrains the exemptions to 12 months from commencement (r 6(2)).

The Schedule appended to the regulations (Schedule 1) enumerates a long list of synthetic drugs and class descriptors (for example AB‑001, 5F‑AKB48, Ethylone, 2C‑F, various indazole/indole carboxamides, and several generic class headings). The instrument does not itself create offences, nor does it list penalties; it operates by altering which substances and which subordinate‑instrument provisions are considered to be within the operation of the Commonwealth Act for the statutory purposes identified (r 4(1), r 5(1), r 6(1)). The exemptions are expressly temporary and subject to renewal or further legislative action at or before each 12‑month expiry.

The legislative history records the principal regulations as commencing 23 July 2015 (Gazette 23.7.2015), with further variations inserted by instruments dated 3 December 2015 (inserting r 5) and 12 November 2017 (inserting r 6) (Legislative history table; Provisions varied). The principal 2015 regulations also revoked the Trans‑Tasman Mutual Recognition (South Australia) Regulations 2013 (Legislation revoked by principal regulations). The text of the regulations must therefore be read as a set of temporary, instrumented exemptions that operate via cross‑reference to both the State Act and the Commonwealth Act provisions identified in each regulation.

The instrument rests on three core legal concepts that appear repeatedly in the text: (1) declaration of exemption from the operation of the Commonwealth Act, (2) temporal limitation of those exemptions, and (3) cross‑reference to provisions of an existing South Australian subordinate instrument, the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014, as varied.

1. Exemption from operation of the Commonwealth Act. Each of r 4, r 5 and r 6 states that certain substances and certain provisions of the 2014 Controlled Substances Regulations are “declared to be exempt from the operation of the Commonwealth Act” for the purposes expressly stated (r 4(1), r 5(1), r 6(1)). The phrase is statutory: the regulations do not themselves purport to amend the Commonwealth Act, they instead declare the non‑operation of that Commonwealth instrument with respect to the enumerated items for the specific cross‑statutory purposes identified (that is, “for the purposes of section 5 of the Act and section 46 of the Commonwealth Act” in each regulation).

2. Temporal limitation. Each exemption is expressly temporary: r 4(2), r 5(2) and r 6(2) provide that the exemptions “have effect for a period of 12 months following the commencement of this regulation.” The instrument therefore creates a stream of time‑limited exemptions rather than permanent removals from the operation of the Commonwealth Act. The text makes the duration a function of the commencement date of the particular regulation which contains the exemption, so differing commencement dates (as recorded in the legislative history) yield differing expiry points for different cohorts of exemptions.

3. Cross‑reference to South Australian controlled‑substances subordinate law. The regulations do not operate in isolation: they explicitly exempt not only named chemical substances but also “the provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014” that refer to those substances, with references to the specific variation instruments that inserted those provisions in the 2014 Regulations (r 4(1)(b), r 5(1)(b), r 6(1)(b)). The instrument therefore links the scope of the exemption to the text of another instrument and to its variation history (Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015; Controlled Substances (Controlled Drugs, Precursors and Plants) (Miscellaneous) Variation Regulations 2017).

Other discrete features to note in the regulatory text are the use of both specific chemical names and broad class descriptors (Schedule 1 contains both exact chemical names and class entries such as “Indazole‑3‑carboxamides”), and the inclusion of parenthetical alternative names and acronyms (for example “alpha‑PVP or alpha‑pyrrolidinovalerophenone”). The regulations therefore employ both narrow and expansive textual devices to capture particular molecular entities and families of related molecules within an exemption. Where the regulation uses a phrase such as “not otherwise listed in Schedule 1 of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014” (r 6(3)(e)-(f)), it introduces an express cross‑cutting qualification that links the scope of the SA exemption to the content of that Commonwealth‑referenced Schedule.

The regulations change the legal status of the listed substances and of the relevant provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 insofar as the Commonwealth Act would otherwise operate. Who is most directly affected by that legal change is determined by the statutory operation of the Act and the Commonwealth Act referenced in the text; the regulations themselves identify the objects of exemption but not the downstream enforcement or licensing regimes. From the text, the groups and interests directly implicated are:

• Persons, businesses and entities dealing with the specific substances or preparations named. The regulations declare particular chemical entities and any preparations containing them to be exempt from operation of the Commonwealth Act (r 4(1)(a), r 5(1)(a), r 6(1)(a)). That declaratory step alters, for those persons, the interaction between the Commonwealth Act and the listed substances for the statutory purposes identified. Where a business manufactures, supplies, imports, exports, possesses or otherwise handles substances that are in Schedule 1 or in the r 6(3) list (for example acetyl fentanyl, ethylone, MDMB‑CHMICA, U‑47700, or broader classes such as “Indazole‑3‑carboxamides”), those businesses are the primary private actors affected by the exemptions.

• Parties relying on mutual recognition arrangements that rest on section 5 of the SA Act and section 46 of the Commonwealth Act. Each regulation opens with the formula “For the purposes of section 5 of the Act and section 46 of the Commonwealth Act” (r 4(1), r 5(1), r 6(1)). Any person whose rights, regulatory authorisations or commercial activities would otherwise be governed by the interaction of those two statutory provisions should be aware that these regulations alter the Commonwealth Act’s operation with respect to the named substances for those purposes.

• Regulators and administrators charged with applying the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 in South Australia. The regulations declare particular provisions of the 2014 Regulations (as inserted by specified Variation Regulations) to be exempt from the Commonwealth Act (r 4(1)(b), r 5(1)(b), r 6(1)(b)). That is an instrument‑level change that affects how the 2014 Regulations interface with Commonwealth mutual‑recognition arrangements. Regulatory bodies implementing the 2014 Regulations will need to record that those particular provisions are excluded from the Commonwealth Act’s operation for the periods stated.

The regulations are primarily declaratory and temporal; they do not, on their face, impose new affirmative duties or create standalone rights in the way that a primary Act or an offence provision would. Instead, the principal legal effects are to alter which substances and which subordinate‑instrument provisions fall within the operation of the Commonwealth Act for the specified statutory purposes. From the text, the following duties and rights (or the lack of them) arise and should be recorded for practitioners:

Rights and legal effects created or modified by the regulations

• Exemption status. Persons handling any substance listed in Schedule 1, MDMB‑CHMICA as named in r 5(1)(a), or any substance listed at r 6(3) (and preparations containing those substances) are declared to be exempt from the operation of the Commonwealth Act for the purposes of s 5 of the SA Act and s 46 of the Commonwealth Act during the 12‑month period that begins on the commencement date of the particular regulation (r 4(1)(a), r 5(1)(a), r 6(1)(a); r 4(2), r 5(2), r 6(2)). That is a statutory declaration of the scope of the Commonwealth Act’s operation, and therefore modifies the external legal landscape for those substances during the stated period.

• Exemption of related subordinate provisions. The regulations expressly declare to be exempt from the Commonwealth Act the particular provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 that were inserted by the Variation Regulations cited in each regulation (r 4(1)(b), r 5(1)(b), r 6(1)(b)). For an administrator or regulated person, this means the linkage between the 2014 Regulations and the Commonwealth Act is altered for the provisions that specifically refer to the substances listed.

Duties and compliance implications implicit in the text

• Duty to identify and classify. Because the exemptions are substance‑specific and because Schedule 1 includes both narrow names and broad class descriptors, regulated persons have an implicit duty to determine whether a product or preparation falls within the enumerated descriptions. The instrument itself depends on that classification to take effect; therefore, affected parties must undertake accurate identification and record‑keeping to know whether they fall inside or outside the exemption window (Schedule 1; r 6(3)).

• Monitoring duty for temporal expiry. Each exemption lasts 12 months from commencement (r 4(2), r 5(2), r 6(2)). The start dates differ by regulation (see Legislative history: commencement entries). Practitioners have a duty (operationally speaking) to monitor the expiry of each exemption and to take appropriate action (for example, cease certain activity or seek clarification) when an exemption lapses. The regulations do not automatically extend past 12 months; the instrument places the risk of temporal lapse on those whose activities depend on the exemption.

The text of the Trans‑Tasman Mutual Recognition (South Australia) Regulations 2015, as supplied, contains no express penalty or enforcement provisions. The regulations operate by declaring exemptions from the operation of the Commonwealth Act and by declaring that certain provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 are exempt from the operation of the Commonwealth Act (r 4(1)(a)-(b), r 5(1)(a)-(b), r 6(1)(a)-(b)). The instrument therefore changes the legal interplay between instruments but does not itself provide an enforcement mechanism. From the text the following points about penalties and enforcement emerge:

• Absence of direct penalties in the instrument. No clause in r 1-6 or Schedule 1 supplies a penalty, an offence, or an enforcement schedule. The regulations are declaratory and temporal in character. Consequently, any penalty or enforcement consequence for conduct involving the listed substances is governed by the provisions of the Act, the Commonwealth Act, the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014, or other relevant primary or subordinate legislation that remain in force and applicable. The regulations indicate which provisions are excluded from the Commonwealth Act for the purposes named, but do not themselves change enforcement powers or penalties.

• Enforcement remains governed by underlying statutes and instruments. Because the regulations declare which provisions or substances are to be treated as exempt from the Commonwealth Act, determining which enforcement provisions apply in practice requires consultation of: (a) the Trans‑Tasman Mutual Recognition (South Australia) Act 1999 (for the meaning of the relevant cross‑references such as s 5 of the Act), (b) the Commonwealth Act and its relevant provisions (for example s 46 as cited), and (c) the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 and the variation regulations referred to by these regulations. The instrument’s legal text points to this architecture but does not itself resolve which enforcement body, process or penalty applies to a particular factual situation.

• Enforcement uncertainty where exemptions overlap or lapse. Because the exemptions are temporary (12 months from commencement of each regulation) (r 4(2), r 5(2), r 6(2)), enforcement status for a particular substance may change over time. During an exemption period, an enforcement body exercising powers under an instrument that is declared to be exempt will need to determine whether that exemption affects its jurisdiction or powers; after expiry, the enforcement landscape may revert. The regulations therefore introduce potential temporal complexity into enforcement decision‑making, but they do not allocate enforcement responsibility or set new penalties.

The regulations are expressly framed as cross‑instrument modifiers: they change how the Commonwealth Act operates in relation to particular substances and particular provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014. The interaction is therefore a matter of statutory layering and temporal coordination. The following points are supported by the text and set out the concrete interaction mechanisms:

• Direct cross‑reference to the Commonwealth Act and the State Act. Each of r 4, r 5 and r 6 is framed “For the purposes of section 5 of the Act and section 46 of the Commonwealth Act” (r 4(1), r 5(1), r 6(1)). This establishes that the instrument’s legal effect is tied to the interaction of those two provisions. The regulations therefore operate as an instrument that changes the operation of the Commonwealth Act , but only for the statutory purposes described in those cross‑references. The regulations do not purport to amend the Commonwealth Act; they declare exemptions from its operation for those purposes.

• Interaction with the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014. Each regulation declares specific provisions of the 2014 Regulations , specifically those provisions inserted by particular Variation Regulations , to be exempt from the operation of the Commonwealth Act (r 4(1)(b), r 5(1)(b), r 6(1)(b)). This is a two‑way tie: the exclusion applies to the Commonwealth Act in relation to the 2014 instrument, and the 2014 instrument is itself the reference point for classifying and regulating the substances. Practically, this creates an interaction in which the 2014 Regulations remain the operative local text, but the Commonwealth Act’s reach in relation to the listed substances and inserted provisions is suspended for the time being.

• Cross‑referencing to Variation Regulations. The regulations identify specific Variation Regulations that inserted the 2014 provisions now declared exempt: the Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015 (referred to in r 4 and r 5) and the Controlled Substances (Controlled Drugs, Precursors and Plants) (Miscellaneous) Variation Regulations 2017 (referred to in r 6). The exemptions therefore mirror the temporal life and content of those particular variation instruments, meaning that any later changes to the 2014 Regulations (by further variation instruments) could alter the scope of the exemption if those later instruments are not themselves captured or if a separate exemption is not made.

The text includes a legislative history section that records the principal instrument, variations and some consequential editorial omissions. The relevant entries in the legislative history portion of the text are the authoritative record within this instrument and supply the dates for commencement and the introductions of r 5 and r 6. Extracting the concrete chronology from the provided material:

• Principal regulations and commencement. The Trans‑Tasman Mutual Recognition (South Australia) Regulations 2015 were made as No 188 and appeared in the Gazette 23 July 2015 at p 3548. The commencement entry records “23.7.2015: r 2” (Legislative history table). The principal 2015 regulations revoked the earlier Trans‑Tasman Mutual Recognition (South Australia) Regulations 2013 (Legislation revoked by principal regulations).

• Variation inserting r 5 (MDMB‑CHMICA). Regulation 5 was inserted by instrument No 244 of 2015 (Gazette 3 December 2015 p 5163). The commencement note for that variation is “3.12.2015: r 2” (Legislative history table; Provisions varied: r 5 inserted by 244/2015 r 4, commencement 3.12.2015). This is the source of the MDMB‑CHMICA‑specific exemption in r 5.

• Variation inserting r 6 (certain controlled drugs). Regulation 6 was inserted by instrument No 305 of 2017 (Gazette 7 November 2017 p 4548). The commencement date for that variation is “12.11.2017: r 2” (Legislative history table; Provisions varied: r 6 inserted by 305/2017 r 4, commencement 12.11.2017). This is the source of the r 6 list of fentanyl derivatives, benzamides and related substances.

• Omissions and editorial revision notes. The legislative history notes that r 2 (the usual commencement provision) was omitted under the Legislation Revision and Publication Regulations 2002 on 3 December 2015, and Sch 2 was omitted under the same revision regulations on that date (Provisions varied list: r 2 omitted 3.12.2015; Sch 2 omitted 3.12.2015). These are editorial/housekeeping amendments that do not alter the substantive exemptions other than to record that the formal r 2 text was removed as part of the legislative revision process.

• Historical consolidated version note. The legislative history lists 3.12.2015 as a historical version reference point (Historical versions). That date corresponds to the insertion of r 5 and to the omitting of certain administrative provisions noted above.

Practical consequence of the amendment trail for compliance and advice: the staggered introduction of r 5 and r 6 means that different exemptions come into effect at different times and therefore expire at different times (each being for 12 months from the commencement of the regulation concerned; r 4(2), r 5(2), r 6(2)). A practitioner must therefore identify which regulation created the exemption relevant to a particular substance and then map the commencement date for that regulation to determine the expiry. The legislative history entries supply those commencement dates (23.7.2015, 3.12.2015, 12.11.2017). The instrument also records the principal regulations’ revocation of the 2013 regulations (Legislation revoked by principal regulations), which is the initial structural change effected by the 2015 instrument.

The legislative text supplied contains no references to litigation, judicial decisions, or case law arising under these regulations. The instrument’s legislative history section records only Gazette notices, revocation of the 2013 regulations, and the insertion/omission of particular provisions by way of variation instruments (Legislative history table; Legislation revoked by principal regulations; Provisions varied). There is no in‑text recording of judicial interpretation, declaratory relief, injunctions, or appeals related to these regulations.

Accordingly, and strictly within the boundaries of the provided material, there is no litigation history recorded in the regulations themselves. Practitioners who require an authoritative account of any judicial developments that may have dealt with these regulations (for example, disputes over whether a particular substance falls within Schedule 1 or within the r 6(3) class descriptors, or challenges to the validity of the exemptions) will need to search court records or a consolidated legal database beyond the content of these regulations. The regulations as provided do not identify any cases, citations, or judicial pronouncements.

It is also relevant to note that the absence of recorded litigation in the instrument does not mean there has been none: it simply means the instrument’s text and its legislative history entries, as provided, contain no reference to litigation. If a client’s matter turns on a judicial construction of “exempt from the operation of the Commonwealth Act,” or on whether a specific chemical falls within a class descriptor in Schedule 1, counsel should confirm whether any decisions have considered these provisions since the last recorded legislative variation.

The regulations create a number of practical traps and technical points that have immediate compliance and operational consequences. These “gotchas” are all grounded in the wording and structure of the instrument and the surrounding legislative history:

• Temporary 12‑month life for each exemption. Each exemption is expressly temporary, “for a period of 12 months following the commencement of this regulation” (r 4(2), r 5(2), r 6(2)). Because r 5 and r 6 were inserted on later dates than the principal instrument (see Legislative history), each exemption cohort has a different expiry date. Failure to track those staggered expiry dates can expose a person to a changed legal landscape overnight when an exemption lapses.

• Differential commencement dates and staggered expiries. The legislative history records commencement dates for the principal regulations and the variations (23.7.2015; 3.12.2015; 12.11.2017). For example, MDMB‑CHMICA‑specific exemptions in r 5 are subject to the 3.12.2015 commencement and therefore expire 12 months from that date, unless renewed. Practitioners must map each substance to the specific regulation that exempts it and then to the commencement date to determine the expiry.

• Broad and class‑based descriptors. Schedule 1 contains many class‑style entries (for example “Indazole‑3‑carboxamides”, “Indole‑3‑carboxylic acid, quinolinyl esters”, “Indol‑3‑yl‑(2,2,3,3‑tetra‑alkylcyclopropyl)methanones”) and r 6 contains items such as “fentanyls (not otherwise listed in Schedule 1 of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014)” (r 6(3)(i)). These broad descriptors can capture unforeseen variants. The legal consequence is that chemical classification requires forensic or technical input to determine whether a substance falls within a class entry, and legal advisers must pay attention to the scope of the class language in Schedule 1 and r 6.

• Cross‑reference phrases that produce two‑way dependence. Phrases such as “not otherwise listed in Schedule 1 of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014” (r 6(3)(e)-(f), r 6(3)(i)) anchor the scope of the SA exemption to the content of another instrument. Changes to that other instrument could therefore alter the logical reach of the exemption. Practitioners must cross‑check both instruments to determine capture.

• Parenthetical alternative names and acronyms. Schedule 1 entries embed numerous alternative common names and acronyms in parentheses (for example “alpha‑PVP or alpha‑pyrrolidinovalerophenone” and “AB‑CHMINACA” entries). This complicates search and classification workflows because a product could be labelled under an alternative synonym and still fall within the Schedule item.

The regulations do not set out a positive compliance regime but they create clear operational steps that regulated entities, advisers and compliance officers should follow to manage legal risk. The following checklist is grounded in the wording of the regulations, the Schedule and the legislative history provided:

1. Map each product or chemical to the instrument. Determine whether the substance or preparation is named in Schedule 1 (Schedule 1 lists numerous synthetic drugs and class descriptors), is MDMB‑CHMICA (r 5(1)(a)), or is one of the substances listed at r 6(3) (for example acetyl fentanyl, butyryl fentanyl, U‑47700, fentanyls, pyrazolam, etc.). The regulations exempt “any preparation containing” a listed substance (r 4(1)(a), r 5(1)(a), r 6(1)(a)), so include formulations and mixtures in the classification.

2. Check class descriptors and cross‑references. If a product contains a molecule that might be captured by class phrases such as “Indazole‑3‑carboxamides” or “fentanyls (not otherwise listed in Schedule 1 of the Controlled Substances...)” (Schedule 1; r 6(3)(i)), obtain forensic/chemical identification to determine whether the product falls within the textual scope. Where the regulation uses “not otherwise listed” language (r 6(3)(e)-(f), r 6(3)(i)), concurrently check Schedule 1 of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 to determine whether the “not otherwise listed” qualifier applies.

3. Record the relevant commencement and expiry dates. Each exemption “has effect for a period of 12 months following the commencement of this regulation” (r 4(2), r 5(2), r 6(2)). Identify which regulation created the exemption for the substance in question (r 4, r 5 or r 6) and map the relevant commencement date from the legislative history (principal regulations 23.7.2015; r 5 insertion 3.12.2015; r 6 insertion 12.11.2017). Enter the appropriate expiry date into compliance calendars well before the 12‑month deadline.

4. Monitor variation instruments and the Controlled Substances Regulations. The regulations declare specific provisions of the Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014 , those inserted by certain Variation Regulations , to be exempt from the Commonwealth Act (r 4(1)(b), r 5(1)(b), r 6(1)(b)). Keep copies of and monitor: (a) the 2014 Regulations, and (b) the Variation Regulations cited (2015 and 2017 instruments), to ensure you are working off the correct textual versions and to identify subsequent amendments that might change scope.